MX2024004525A - Proteinas modificadas y degradadores de proteinas. - Google Patents

Proteinas modificadas y degradadores de proteinas.

Info

Publication number
MX2024004525A
MX2024004525A MX2024004525A MX2024004525A MX2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A MX 2024004525 A MX2024004525 A MX 2024004525A
Authority
MX
Mexico
Prior art keywords
protein
degradators
modified proteins
binding
compounds
Prior art date
Application number
MX2024004525A
Other languages
English (en)
Spanish (es)
Inventor
Liqun Chen
Jing Liu
Chengwei Zhang
Ting Yang
Matthew Randolph Lee
Michael Bruno Plewe
Jialiang Wang
Xiaoran Han
Jing Zhou
Jie Ding
Original Assignee
Cullgen Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cullgen Shanghai Inc filed Critical Cullgen Shanghai Inc
Publication of MX2024004525A publication Critical patent/MX2024004525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004525A 2021-10-14 2022-10-13 Proteinas modificadas y degradadores de proteinas. MX2024004525A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021123848 2021-10-14
CN2021133363 2021-11-26
PCT/CN2022/125080 WO2023061440A1 (en) 2021-10-14 2022-10-13 Modified proteins and protein degraders

Publications (1)

Publication Number Publication Date
MX2024004525A true MX2024004525A (es) 2024-05-24

Family

ID=85987275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004525A MX2024004525A (es) 2021-10-14 2022-10-13 Proteinas modificadas y degradadores de proteinas.

Country Status (9)

Country Link
US (1) US20250235543A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416145A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537394A (cg-RX-API-DMAC7.html)
CN (1) CN118451078A (cg-RX-API-DMAC7.html)
AU (1) AU2022362494A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234615A1 (cg-RX-API-DMAC7.html)
IL (1) IL312013A (cg-RX-API-DMAC7.html)
MX (1) MX2024004525A (cg-RX-API-DMAC7.html)
WO (1) WO2023061440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2024072794A1 (en) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions
CN121005703A (zh) * 2024-05-24 2025-11-25 中国科学院广州生物医药与健康研究院 一种酰胺吲嗪类化合物及其制备方法和应用
WO2026107421A1 (en) * 2024-11-18 2026-05-21 Bristol-Myers Squibb Company 1 h-benzo[d]imidazole derivatives as camk2 inhibitors for the treatment of heart failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201522337A (zh) * 2013-03-12 2015-06-16 Arqule Inc 經取代之三環吡唑並-嘧啶化合物類
WO2017185031A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US11191741B2 (en) * 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CA3103185A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2020092662A1 (en) * 2018-11-02 2020-05-07 The Wistar Institute Of Anatomy And Biology Proteolysis-targeting chimeras
EA202192260A1 (ru) * 2019-02-15 2021-12-17 Инсайт Корпорейшн Биомаркеры циклин-зависимой киназы 2 и их применение
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
JP2022529700A (ja) * 2019-04-23 2022-06-23 ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド サイクリン依存性キナーゼ12(cdk12)の分解剤およびその使用
CN112409376A (zh) * 2019-08-20 2021-02-26 华东师范大学 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用
WO2021061151A1 (en) * 2019-09-27 2021-04-01 Romark Laboratories L.C. Screening for anti-hepatitis b compounds
CN114502534A (zh) * 2019-09-30 2022-05-13 协和麒麟株式会社 Bet降解剂
WO2021239117A1 (en) * 2020-05-28 2021-12-02 Cullgen (Shanghai) , Inc. Modified proteins and protein degraders
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
TW202423914A (zh) * 2022-08-19 2024-06-16 美商凱麥拉醫療公司 Cdk2降解劑及其用途
US20240174665A1 (en) * 2022-08-19 2024-05-30 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
CN118451078A (zh) 2024-08-06
AU2022362494A1 (en) 2024-05-23
EP4416145A4 (en) 2026-05-27
CA3234615A1 (en) 2023-04-20
WO2023061440A1 (en) 2023-04-20
JP2024537394A (ja) 2024-10-10
IL312013A (en) 2024-06-01
EP4416145A1 (en) 2024-08-21
US20250235543A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
WO2019136180A3 (en) Heteroduplex nucleic acid molecules and uses thereof
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
BR112019023855A2 (pt) proteínas de ligação à mesotelina
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1117161T1 (el) Βελτιωμενοι κυτταροτοξικοι παραγοντες οι οποιοι περιεχουν νεα μεϋτανσινοειδη
DE602004031714D1 (de) Anthracyclin-anti-cd74-antikörperkonjugate
EP2453908A4 (en) BIFUNCTIONAL STACKED POLYPEPTIDES AND USES THEREOF
MX2022003217A (es) Conjugados terapeuticos.
CY1119412T1 (el) Μεθοδοι για την αξιολογηση μιας ανοσοαποκρισης σε εναν θεραπευτικο παραγοντα
CL2023000554A1 (es) Proteínas diseñadas y métodos de uso de las mismas.
BRPI0508068A (pt) moléculas de ácido nucléico isoladas, vetor compreendendo as mesmas, polipeptìdeos isolados e composições compreendendo os mesmos
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
CY1116413T1 (el) Καινοφανη πληρως-ανθρωπινα μονοκλωνικα αντισωματα anti-vap-1
JOP20210159A1 (ar) أجسام مضادة لـ pmel17 ومترافقات منها
BR112022019689A2 (pt) Citocinas il-2 mascaradas, citocina mascarada, produtos de clivagem, ácido nucleico, vetor, célula hospedeira, composição, kit e métodos de produção de uma citocina il-2 mascarada e de tratamento ou prevenção de câncer
BR112023023650A2 (pt) Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras
CL2023001667A1 (es) Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos
BR112023022315A2 (pt) Quimeras direcionadas à desubiquitinase e métodos relacionados
CL2025003762A1 (es) Formulaciones que comprenden proteína de unión al transcripto 7 similar a inmunoglobulina.
MX2024006205A (es) Composiciones que comprenden agentes de unión multiespecíficos potenciados para una respuesta inmunitaria.
MX2021010577A (es) Compuestos de union a pd-l1 multivalentes para tratar cancer.
CO2025000232A2 (es) Anticuerpos anti-mesotelina
ECSP11010772A (es) Inhibidor de infección